The P-III (IKEMA) trial evaluating Sarclisa + carfilzomib & dexamethasone vs Kd in 302 patients with relapsed MM across 69 centers spanning 16 countries
The results showed an m-PFS of 35.7mos. vs 19.2mos., m-PFS (41.7mos. vs 20.8mos.), time to next treatment (44.9mos.) @25mos., safety & tolerability were consistent with the safety profile of Sarclisa in other clinical trials with no new safety signals, treatment exposure was 30wks. longer, TEAEs of ≥ grade 3 (83.6% vs 73%), serious TEAEs (70.1% vs 59.8%) with no difference after exposure adjustment
The results will also be presented at ESMO 2022. Sarclisa was approved in multiple countries in combination with carfilzomib & dexamethasone including in the US & EU for MM
Ref: Sanofi | Image: Sanofi
